{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:30:27Z","timestamp":1790497827176,"version":"4.1.0"},"reference-count":67,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.2217\/imt.13.20","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T14:00:36Z","timestamp":1365084036000},"page":"395-405","source":"Crossref","is-referenced-by-count":10,"title":["Radioimmunotherapy for Peritoneal Cancers"],"prefix":"10.1080","volume":"5","author":[{"given":"Christof","family":"Seidl","sequence":"first","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen, Department of Nuclear Medicine, Ismaninger Strasse 22, 81675Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Essler","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen, Department of Nuclear Medicine, Ismaninger Strasse 22, 81675Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2013,4,4]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.1148\/rg.292085189"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.4.4.389"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.45"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010701)92:1<71::AID-CNCR1293>3.0.CO;2-9"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s005340100026"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052985"},{"key":"e_1_3_2_3_9_1","first-page":"631","volume":"113","author":"Esquivel J","year":"1993","unstructured":"Esquivel J , Vidal-JoveJ, StevesMA, SugarbakerPH. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery113 , 631\u2013636 (1993).","journal-title":"Surgery"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20013"},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.56.4.226"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-011-0286-y"},{"key":"e_1_3_2_3_13_1","first-page":"1944","article-title":"Radioimmunotherapy targeting of HER2\/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.","volume":"38","author":"Horak E","year":"1997","unstructured":"Horak E , HartmannF, GarmestaniK et al. Radioimmunotherapy targeting of HER2\/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J. Nucl. Med. 38 , 1944\u20131950 (1997).","journal-title":"J. Nucl. Med."},{"key":"e_1_3_2_3_14_1","first-page":"5084","volume":"63","author":"Borchardt PE","year":"2003","unstructured":"Borchardt PE , YuanRR, MiedererM, McDevittMR, ScheinbergDA. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res.63 , 5084\u20135090 (2003).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.7.1.5132"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.06.023"},{"key":"e_1_3_2_3_17_1","first-page":"1342","article-title":"Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: outcome related to measured tumor size and mean absorbed dose.","volume":"47","author":"Elgqvist J","year":"2006","unstructured":"Elgqvist J , AnderssonH, B\u00e4ckT et al. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: outcome related to measured tumor size and mean absorbed dose. J. Nucl. Med. 47 , 1342\u20131350 (2006).","journal-title":"J. Nucl. Med."},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2009.0618"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/394913"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2011.07.003"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0985"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2000.15.53"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1486"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26321"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.086819"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1226"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2005.20.557"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0671"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2300"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0256"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24793"},{"key":"e_1_3_2_3_32_1","first-page":"S989","volume":"50","author":"Esteban JM","year":"1990","unstructured":"Esteban JM , HyamsDM, BeattyBG, MerchantB, BeattyJD. Radioimmunotherapy of human colon carcinomatosis xenograft with 90Y-ZCE025 monoclonal antibody: toxicity and tumor phenotype studies. Cancer Res.50(Suppl. 3) , S989\u2013S992 (1990).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_33_1","first-page":"1224","article-title":"Biodistribution and therapeutic efficacy of 125\/131I-, 186Re-, 88\/90Y-, or 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.","volume":"45","author":"Koppe MJ","year":"2004","unstructured":"Koppe MJ , BleichrodtRP, SoedeAC et al. Biodistribution and therapeutic efficacy of 125\/131I-, 186Re-, 88\/90Y-, or 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J. Nucl. Med. 45 , 1224\u20131232 (2004).","journal-title":"J. Nucl. Med."},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2006.21.506"},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2003.tb01498.x"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0b013e328013e5a8"},{"key":"e_1_3_2_3_37_1","first-page":"1867","volume":"47","author":"Koppe MJ","year":"2006","unstructured":"Koppe MJ , HendriksT, BoermanOC, OyenWJ, BleichrodtRP. Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. J. Nucl. Med.47 , 1867\u20131874 (2006).","journal-title":"J. Nucl. Med."},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-008-0070-4"},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph5010001"},{"key":"e_1_3_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0607"},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874471010801030215"},{"key":"e_1_3_2_3_42_1","first-page":"2804","article-title":"Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer.","volume":"61","author":"Senekowitsch-Schmidtke R","year":"2001","unstructured":"Senekowitsch-Schmidtke R , SchuhmacherC, BeckerKF et al. Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer. Cancer Res. 61 , 2804\u20132808 (2001).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_43_1","first-page":"S3922","article-title":"Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.","volume":"9","author":"Huber R","year":"2003","unstructured":"Huber R , SeidlC, SchmidE et al. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody. Clin. Cancer Res. 9(10 Pt 2) , S3922\u2013S3928 (2003).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00525.x"},{"key":"e_1_3_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-006-0311-3"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1004-0017"},{"key":"e_1_3_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1639-2"},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.080226"},{"key":"e_1_3_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.11.11"},{"key":"e_1_3_2_3_50_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.062604"},{"key":"e_1_3_2_3_51_1","first-page":"3","article-title":"Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas.","volume":"8","author":"Yin BW","year":"2008","unstructured":"Yin BW , KiyamovaR, ChuaR et al. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun. 8 , 3 (2008).","journal-title":"Cancer Immun."},{"key":"e_1_3_2_3_52_1","first-page":"1433","article-title":"Distribution of radiolabeled monoclonal antibody MX35 F(ab\u2018)2 in tissue samples by storage phosphor screen image analysis: evaluation of antibody localization to micrometastatic disease in epithelial ovarian cancer.","volume":"3","author":"Finstad CL","year":"1997","unstructured":"Finstad CL , LloydKO, FedericiMG et al. Distribution of radiolabeled monoclonal antibody MX35 F(ab\u2018)2 in tissue samples by storage phosphor screen image analysis: evaluation of antibody localization to micrometastatic disease in epithelial ovarian cancer. Clin. Cancer Res. 3 , 1433\u20131442 (1997).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_53_1","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1993.1247"},{"key":"e_1_3_2_3_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1989.tb03251.x"},{"key":"e_1_3_2_3_55_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1438.2000.99510.x"},{"key":"e_1_3_2_3_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.5973"},{"key":"e_1_3_2_3_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22663"},{"key":"e_1_3_2_3_58_1","first-page":"S3249","article-title":"A Phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma.","volume":"5","author":"Mah\u00e9 MA","year":"1999","unstructured":"Mah\u00e9 MA , FumoleauP, FabbroM et al. A Phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin. Cancer Res. 5(Suppl. 10) , S3249\u2013S3253 (1999).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_59_1","first-page":"953","article-title":"Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.","volume":"5","author":"Rosenblum MG","year":"1999","unstructured":"Rosenblum MG , VerschraegenCF, MurrayJL et al. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin. Cancer Res. 5 , 953\u2013961 (1999).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_60_1","first-page":"1491","article-title":"Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49.","volume":"37","author":"Meredith RF","year":"1996","unstructured":"Meredith RF , PartridgeEE, AlvarezRD et al. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J. Nucl. Med. 37 , 1491\u20131496 (1996).","journal-title":"J. Nucl. Med."},{"key":"e_1_3_2_3_61_1","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1996.4577"},{"key":"e_1_3_2_3_62_1","first-page":"2806","article-title":"A Phase I study of combined modality 90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.","volume":"8","author":"Alvarez RD","year":"2002","unstructured":"Alvarez RD , HuhWK, KhazaeliMB et al. A Phase I study of combined modality 90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin. Cancer Res. 8 , 2806\u20132811 (2002).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_63_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2011.1111"},{"key":"e_1_3_2_3_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2004.06.013"},{"key":"e_1_3_2_3_65_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874471011104030186"},{"key":"e_1_3_2_3_66_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874471011104030266"},{"key":"e_1_3_2_3_67_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874471011104030261"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt.13.20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T10:23:48Z","timestamp":1715941428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt.13.20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.2217\/imt.13.20"],"URL":"https:\/\/doi.org\/10.2217\/imt.13.20","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}